Russell Cohen to Biosimilar Pharmaceuticals
This is a "connection" page, showing publications Russell Cohen has written about Biosimilar Pharmaceuticals.
Connection Strength
0.581
-
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. Adv Ther. 2025 Mar; 42(3):1360-1392.
Score: 0.219
-
A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body. Immunotherapy. 2023 12; 15(18):1501-1509.
Score: 0.202
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.160